Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia
NCT ID: NCT01598181
Last Updated: 2017-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2011-12-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Modulation of an Experimental Prolonged Pain Model Using High Definition Transcranial Direct Current Stimulation
NCT04650048
Effect of tDCS in Intrinsic Functional Brain Connectivity Assessed by Functional Magnetic Resonance in Fibromyalgia
NCT03841227
Effects of Transcranial Direct Current Stimulation on Pain Perception
NCT01860950
Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis
NCT03219073
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
NCT04084795
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Transcranial Direct Current Stimulation (tDCS) is a non-invasive and safe method for inducing changes in cortical excitability. Previous studies showed that anodal stimulation of M1 may change pain perception, possibly by modulating functional anomalies in the FIM brain. The present study has two main goals:
1. To investigate if tDCS may provide FIM patients with symptom relief due to reduction of pain.
2. To investigate tDCS induced functional changes in the brain by using fMRI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active tDCS
tDCS NeuroConn DC-stimulator plus
Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
sham tDCS
tDCS fades out after 20 sec. administered double blind by coded program.
tDCS NeuroConn DC-stimulator plus
Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
sham tDCS
similar montage and time as active. Stimulation fades out after 20 sec.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tDCS NeuroConn DC-stimulator plus
Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
sham tDCS
similar montage and time as active. Stimulation fades out after 20 sec.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mean VAS \> 4 daily 2 weeks prior to study).
Exclusion Criteria
* CNS disease
* Mental retardation
* Age \< 18
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stiftelsen Helse og Rehabilitering
OTHER
University Hospital of North Norway
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Per Aslaksen, ph.d
Role: STUDY_CHAIR
University of Tromso
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of North Norway
Tromsø, Tromsoe, Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UNorthNorway
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2010/2256/REK n
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.